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ORIGINAL ARTICLE
The glutathione synthesis inhibitor buthionine sulfoximine
synergistically enhanced melphalan activity against preclinical
models of multiple myeloma
A Tagde1,2, H Singh1,3, MH Kang1,2,3 and CP Reynolds1,2,3,4,5
Melphalan (L-PAM) has been an integral part of multiple myeloma (MM) treatment as a conditioning regimen before stem cell
transplant (SCT). After initial response, most treated patients experience relapse with an aggressive phenotype. Increased
glutathione (GSH) in MM may mediate resistance to L-PAM. We demonstrated that the GSH synthesis inhibitor buthionine
sulfoximine (BSO) synergistically enhanced L-PAM activity (inducing 2–4 logs of cell kill) against nine MM cell lines (also in the
presence of marrow stroma or cytokines) and in seven primary MM samples (combination indices o1.0). In MM cell lines, BSO
signiﬁcantly (Po0.05) depleted GSH, increased L-PAM-induced single-strand DNA breaks, mitochondrial depolarization, caspase
cleavage and apoptosis. L-PAM depleted GSH, but GSH rapidly recovered in a L-PAM-resistant MM cell line unless also treated with
BSO. Treatment with N-acetylcysteine antagonized BSOþ L-PAM cytotoxicity without increasing GSH. In human MM xenografted
into beige-nude-xid mice, BSO signiﬁcantly depleted MM intracellular GSH and signiﬁcantly increased apoptosis compared with
L-PAM alone. BSOþ L-PAM achieved complete responses (CRs) in three MM xenograft models including maintained CRs 4100
days, and signiﬁcantly increased the median event-free survival relative to L-PAM alone. Combining BSO with L-PAM warrants
clinical testing in advanced MM.
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INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy that accounts
for 63000 annual deaths worldwide.1–3 Treatment regimens
containing high-dose melphalan (L-PAM) supported by stem cell
transplant (SCT) increased response rates and progression-free
survival compared with conventional therapy.2,4 Despite introducing
new agents and strategies, many patients eventually relapse or
become refractory to current therapy.1,5–7 Each successive regimen
achieves a less durable response, suggesting emergence of a
resistant phenotype and therefore MM remains largely incurable.4,5
L-PAM resistance is an multifactorial phenomenon attributed to
reduced drug accumulation, reduced apoptosis, enhanced DNA
repair and enhanced glutathione (GSH)/gluathione-s-transferases.8–13
GSH protects MM cells against L-PAM.8–10,12 The L-PAM-resistant
RPMI-8226/LR-5 cell line demonstrated a twofold increase in GSH
and a sevenfold increase in L-PAM IC50 compared with its L-PAM-
sensitive counter part.8,10 The increased GSH was attributed to
upregulation of the rate-limiting enzyme in GSH synthesis,
g-glutamylcysteine synthetase (g-GCS).10,11 Buthionine sulfoximine
(BSO) is a potent inhibitor of g-GCS.12,14–16 BSO enhanced L-PAM
activity in the RPMI-8226/LR-5 and RPMI-8226/S MM cell lines,8
and in the MOPC-315 murine plasmacytoma.17 Phase I trials of
continuous infusion of BSO induced 480% depletion of tumor
GSH compared with pretreatment levels, but the modest activity
of BSOþ low-dose L-PAM in adult cancers slowed further clinical
development of BSO.12,16,18 A high degree of synergistic
enhancement of L-PAM cytotoxicity in the presence of BSO was
observed in multidrug-resistant neuroblastoma cell lines, including
those that were established at relapse after myeloablative therapy
with L-PAM and lines highly resistant to L-PAM due to loss of p53
function, especially at concentrations of L-PAM that were
myeloablative.19,20 The latter observation led to a recently
completed phase I trial of BSOþ L-PAM given with stem cell
support in the New Approaches to Neuroblastoma Therapy
(NANT) consortium that has safely dose-escalated L-PAM given
with BSO to myeloablative L-PAM doses, with the stem cell
infusions overcoming the expected hematopoietic toxicity
(www.NANT.org; www.clinicaltrials.gov, NCT00002730).
Taken together, preclinical and clinical studies in neuroblastoma
suggest the potential for BSO to enhance L-PAM activity against
diseases that use myeloablative dosing of L-PAM and previous
investigations with one murine plasmacytoma,17 and a human
MM cell line,8,10 demonstrated enhanced activity of L-PAM by
BSO.16,21 Therefore, we have undertaken extensive studies to
determine the potential for BSO to enhance the anti-myeloma
activity of L-PAM at clinically achievable doses using in vitro (cell
lines and fresh MM explants) and in vivo MM xenografts to
determine if BSOþ L-PAM warrants clinical trials in MM.
MATERIALS AND METHODS
Drugs and chemicals
Powdered L-PAM and BSO (DL buthionine-(S,R)-sulfoximine) were
purchased from Sigma-Aldrich (St Louis, MO, USA) and clinical grade
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BSO (L-buthionine (S,R)-sulfoximine (50mg/ml)) was provided by the
National Cancer Institute (Bethesda, MD, USA).22 Interleukin-6, vascular
endothelial growth factor, insulin-like growth factor-1 and Annexin V
assay kit were from Life Technologies (Carlsbad, CA, USA). F7-26 (mAb)
was from Millipore (Billerica, MA, USA).23 The JC-1 probe, vitamin C,
vitamin E, N-acetylcysteine (NAC) and sodium thiosulfate (STS) were from
Sigma-Aldrich. The anti-CD38 phycoerythrin (PE) and anti-CD138
ﬂuorescein isothiocyanate (FITC) antibodies, and APO-DIRECT kit
(terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL)) were purchased from BD Biosciences (San Jose, CA,
USA).23,24 Caspase-3, caspase-9, poly ADP ribose polymerase and anti-
rabbit immunoglobulin G horseradish peroxidase antibodies were from
Cell Signaling (Danvers, MA, USA); anti-b-actin was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Cell culture
Human MM cell lines MM.1S, RPMI-8226, U266 and NCI-H929 were from
ATCC (Manassas, VA, USA) and MOLP-2, KMS-12-PE, OPM-2 and EJM
were from DSMZ (Braunschweig, Germany).25 TX-MM-030h (CD38þ and
CD138þ ) was established in our laboratory from a patient with
progressive MM after receiving L-PAM-based myeloablative therapy and
autologous SCT. EJM and TX-MM-030h were maintained in Iscove’s
modiﬁed Dulbeco’s medium, supplemented with 20% fetal bovine serum
(FBS) and insulin, selenium, transferrin (BD Biosciences) universal culture
supplement (1:1000). MM.1S, RPMI-8226, NCI-H929 and OPM-2 were
maintained in RPMI-1640 medium with 10% FBS. U266 was maintained in
RPMI-1640 15% FBS, while MOLP-2 and KMS-12-PE were in RPMI-
1640þ 20% FBS. All cell lines were grown in antibiotic-free medium and
veriﬁed to be free of mycoplasma (MycoAlert kit, Lonza, Walkersville,
MD, USA). Cell line identity was conﬁrmed at the time of experimentation
by short tandem repeat genotyping and compared with our database of
cell line short tandem repeat proﬁles (www.TXCCR.org). Cells were cultured
and treated in a 37 1C humidiﬁed incubator gassed with 5% CO2 and 90%
N2 so as to achieve bone marrow level hypoxia of 5% O2 or alternatively
room air without N2 to achieve B20% O2.
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Isolation of primary MM cells, bone marrow stromal cell (BMSC)
and co-culture
Clinical specimens were obtained with consent via a biobanking protocol
approved by the TTUHSC committee for protection of human subjects.
Heparnized blood (n¼ 2) and bone marrow aspirates (n¼ 5) were used to
isolate mononuclear cells by Ficoll density gradient centrifugation and
cryopreserved using equal volumes of FBS and 15% dimethylsulphoxide
dissolved in RPMI-1640 medium.27 The cryopreserved cells were cultured
in Iscove’s modiﬁed Dulbeco’s medium supplemented with 20% FBS,
insulin, selenium, transferrin, 10 ng/ml of interleukin-6, insulin-like growth
factor-1 and vascular endothelial growth factor at 5% O2 for 1 week before
sorting primary MM cells. For sorting, mononuclear cells were reacted with
anti-CD38 PE and anti-CD138 FITC antibodies and primary MM cells were
isolated using ﬂuorescence-activated cell sorting (BD FACSAria II, San Jose,
CA, USA). The percentages of MM cells in mononuclear samples were
B5–60%. Isolated MM cells were cultured in Iscove’s modiﬁed Dulbeco’s
medium supplemented with 20% FBS, insulin, selenium, transferrin,
10mg/ml of gentamycin, 10 ng/ml of interleukin-6, insulin-like growth
factor-1 and vascular endothelial growth factor.28
For preparation of BMSCs, adherent cells were long-term cultured and
expanded in Iscove’s modiﬁed Dulbeco’s medium, supplemented with
20% FBS and 10mg/ml of gentamycin. BMSC and MM cells co-cultures used
B104 BMSC per well in a 24-well plate overnight before the addition MM
cells (105).27,28 Once MM cells were attached to the stromal cell layer, BSO
was added to the medium. After 24 h of incubation, L-PAM was added.
The determination of early apoptosis was done at 24 h by aspirating the
MM cells away from the BMSC and using Annexin V assay with ﬂow
cytometry and cytotoxicity at 96 h using DIMSCAN assay as previously
described.24
DIMSCAN cytotoxicity assay
The cytotoxicity of BSO and L-PAM was determined in a ﬁxed-ratio of
concentration (BSO: L-PAM; 8:1) using the DIMSCAN cytotoxicity assay.29–31
The drug concentration ranges used were: BSO, 0–400mM and L-PAM,
0–50mM (clinically achievable levels).21,22,32,33 Cells (1–5 103) or primary
MM cells (B104) were seeded, incubated with BSO for 24 h and followed
by treatment with L-PAM. After incubating for 96 h with the drugs,
ﬂuorescein diacetate and eosin Y were added to the wells, incubated for
20min and total ﬂuorescence in each well was measured by
DIMSCAN.20,24,29
Determination of total GSH (GSHþGSSG) using high-performance
liquid chromatography
Intracellular GSH and GSSG levels were measured using a published
method.34 A derivatization procedure was used using phthalaldehyde.
The separation of derivitized GSH was achieved using a mobile
phase consisting ammonium formate buffer (0.1 M pH 6.0)—methanol
100% (60:40 v/v) at the ﬂow rate of with 0.5ml/min using
the C18 column (Agilent Zorbax Eclipse, Santa Clara, CA, USA;
150 4.6mm, 3.5mm). The eluted derivatives of GSH were detected at
an excitation wavelength of 340 nm and an emission wavelength of
420 nm. The calibration curve was linear over the range 0.156–20mg/ml
with the correlation coefﬁcient 40.995.
Determination of single-strand DNA (ssDNA) breaks, mitochondrial
membrane depolarization, caspase cleavage and DNA fragmentation
Cells were seeded, pretreated with BSO (400 mM) for 24 h followed
by treatment with L-PAM (30 mM). Determination of ssDNA breaks,23
mitochondrial membrane depolarization,24 caspase cleavage24 and
apoptotic DNA fragmentation23 was carried out as previously
described.23,24
In vivo activity testing against human MM xenografts
Studies were carried out in the TTUHSC Laboratory Animal Resources
Center under protocols approved by the Institutional Animal Care and
Use Committee. Six- to eight-week-old female NCI beige-nude-xid
(Bethesda, MD, USA) mice were subcutaneously inoculated between
shoulder blades with 25–30 106 MM cells using matrigel (BD
Biosciences). When tumors achieved a size of X100mm3, mice were
randomized into four groups. BSO (50mg/ml) was diluted in sterile 0.9%
w/v saline. Powdered L-PAM was dissolved in 0.1 N HCl ethanol and
diluted in saline immediately before injection. Controls received vehicle
only, BSO-only group received 125mg/kg twice daily on days 1, 2 and 3
via intraperitoneal injection, L-PAM-only group received 10mg/kg dose
on days 2 and 3 given intravenously into the lateral tail vein, and the
L-PAMþ BSO group received both drugs as per above. Tumor volume
was measured twice weekly using the formula ½ length breadth
height.35,36 Mice were weighed twice weekly to assess toxicity and killed
when tumors reached 1500mm3 or they experienced any severe
morbidity (that is, body weight o17 g).
Determination of responses and event deﬁnitions for MM
subcutaneous xenograft model
Responses were assessed as previously described.37 Complete response
(CR) was deﬁned as disappearance of a measurable tumor mass
(o50mm3) for at least one time point; a CR was considered as a
maintained (maintained CR (MCR)), if maintained (o50mm3) for 100 days.
Partial response was deﬁned as tumor volume regression X50% from
initial volume for at least one time point during therapy but with a
measurable tumor mass. Mouse event-free survival (EFS) was calculated as
the number of days from treatment initiation until the tumor volume
reached 1500mm3, death from any cause or morbidity that required
killing. An EFS T/C was calculated as the ratio of median time to event of
the treatment group to the median time to event of the controls. High
activity was: (a) EFS T/C ratio42, (b) a signiﬁcant difference (Po0.05) was
observed in the EFS distribution between treatment and control groups
and (c) a net reduction in tumor volume in treated vs controls at the end
of treatment was observed. Agents meeting the ﬁrst two criteria but not
having a net reduction in the median tumor volume for treated animals
at the end of study were considered as moderately active. An EFS T/Co2
was regarded as low activity. Relative tumor volume (RTV) was calculated
when all or a majority of mice in control and treatment group had a
measurable tumor (days 8–9). The tumor volume T/C value was the mean
RTV for the treatment group to that of mean RTV for control group.
Agents producing T/C of o45% were regarded as highly active, 45–60%
were considered to have moderate activity and 460% were considered
to have low activity.
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RESULTS
BSO synergistically enhanced L-PAM-induced cytotoxicity in nine
MM cell lines, in presence of BMSC and MM cytokines, and in
seven primary MM cells
We determined the cytotoxicity of clinically achievable levels of
BSO (0–400 mM) and L-PAM (0–50 mM) in nine human MM cell lines
using the DIMSCAN cytotoxicity assay (Figure 1a). L-PAM as a
single agent was highly active against MM.1S, KMS-12-PE, MOLP-2
and NCI-H929, inducingX2 logs of cell kills at the maximum dose
(50 mM). In the remaining ﬁve cell lines, L-PAM showed modest
activity and inducedp2 logs of cell kill. BSO alone had minimal to
no activity in six cell lines and had modest activity in the OPM-2,
KMS-12-PE and MM.1S lines. The combination of BSOþ L-PAM
achieved synergistic cytotoxicity (combination index number (CIN)
Figure 1. Representative dose response curves of BSO (black circles), L-PAM (white circles) and BSOþ L-PAM (black triangles) in nine MM cell
lines. (a) Drug concentrations were 0–400 mM for BSO and 0–50 mM for L-PAM (Fixed ratio, BSO: L-PAM: 8:1). Cultures were treated with BSO for
24 h, at which time L-PAM was added, followed by 96 h of incubation before DIMSCAN cytotoxicity analysis. Cell lines were cultured in bone
marrow level hypoxia (5% O2). The survival fraction was determined by mean fluorescence of the treated cells/mean fluorescence of control
cells. Error bars represent s.d. (nX3). (b) Summary of cytogentic abnormality of MM cell lines (c) CINs were calculated for fixed ratio of BSO and
L-PAM (8:1) using CalcySyn software (Biosoft, Cambridge, UK). The CIN values o1 indicate synergism and 41 indicate antagonism effect.
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p0.7) and induced 2–4 logs of cell kill in all nine MM cell
lines including the eight lines established at progressive
disease (PD) after therapy (U266, OPM-2, NCI H929, KMS-12-PE,
EJM, TX-MM-030h, MM.1S and MOLP-2),25 which include lines
with cytogenetic proﬁles associated with a poor prognosis
(Figure 1b).25,38,39 The combination of BSO (200 mM) and L-PAM
(25 mM) achieved very strong synergism (CIN p0.1) in RPMI-8226
(TP53, KRAS and EGFR mutations) and U266 (TP53-mutation)
cell lines,38,40 and strong synergism (CIN 0.1–0.3) was seen in
MM.1S (TP53-wt and t(14;16)), KMS-12-PE (t(11;14) (q13;q32))
and EJM (TP53-mutation).25,38,40 BSOþ L-PAM was synergistic
(CIN 0.3–0.7) in OPM-2 (t(4;14)(p16;q32)), NCI-H929 (t(4;14))
TX-MM-030h (post-BMT) and MOLP-2 (t(11;14)(q13;q32))39 cell
lines (Figures 1a–c).25,38 Identical results were also obtained for all
cell lines tested with BSOþ L-PAM when cultured in ‘standard’
culture conditions (room airþ 5% CO2; Supplementary Figure 1).
We assessed whether the activity of BSOþ L-PAM is attenuated
by co-culture with MM cytokines (interleukin-6, insulin-like
growth factor-1 and vascular endothelial growth factor) and
BMSCs. In all four cell lines tested, BSOþ L-PAM signiﬁcantly
(Po0.05) enhanced % apoptotic cells (Annexin Vþ and PIþ / )
as compared with L-PAM (Figure 2a). Similar to the observation in
MM cell lines, the combination treatment induced multi-logs of
synergistic cell kill (CIN o1.0) (Figures 2b and c). Next, we
determined the efﬁcacy of BSOþ L-PAM in freshly isolated
primary MM cells from clinical specimens. Consistent with the
effects in MM cell lines, pretreatment with BSO synergistically
(CIN o 1.0) enhanced L-PAM-induced cytotoxicity in all primary
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Figure 2. Four MM cell lines were cultured in presence of BMSCs and MM cytokines (interleukin-6 (IL-6), vascular endothelial growth factor
(VEGF) and insulin-like growth factor-1 (IGF-1)) at the concentrations of 10 ng/ml. (a) The percentage of apoptosis in MM cells (aspirated away
from the BMSC) was determined using Annexin V assay and flow cytometry at 24 h after the treatment with BSO (400 mM) and L-PAM (30 mM).
Bars represent percentage of cell undergoing apoptosis (Annexin Vþ and PIþ / ). Error bars represent s.d. (nX3) and asterisk represent
statistical difference in means (Po0.05). (b) Cells were treated with BSO (0–400 mM), L-PAM (0–50 mM) and BSOþ L-PAM. At the end of 96 h, MM
cells were carefully aspirated off of the BMSC, plated in 96-well plates, and assayed for cytotoxicity using DIMSCAN. Error bars represent s.d.
(nX3). (c) The CINs were determined using for the fixed ratio of BSO and L-PAM (8:1).
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MM cells, including in samples obtained from patients who
had signiﬁcant prior exposure to chemotherapy and had SCT
(Figures 3a–c).
BSO enhanced L-PAM-induced ssDNA breaks and mitochondrial
depolarization
To understand the mechanism of enhanced cytotoxicity of L-PAM
in the presence of BSO, we determined ssDNA breaks induced by
L-PAM±BSO.23 In all four cell lines tested, BSO signiﬁcantly
increased (Po0.05) L-PAM-induced ssDNA breaks compared with
L-PAM only (Figures 4a and b). For instance, in the MM.1S cell line,
the cells with ssDNA breaks (Figure 4a, quadrant 4; FITCþ /PI )
showed 5.2±0.2% in controls, 8.6±0.4% with 400 mM of BSO
treatment, 50.19±1.3% in presence of 30 mM of L-PAM and
64.6±2.2% with BSOþ L-PAM (Po0.05). Similarly, in OPM-2, KMS-
12-PE and U266 cell lines, BSOþ L-PAM signiﬁcantly increased
(Po0.05) ssDNA breaks relative to single agents and controls.
As apoptosis has been reported as a primary mechanism of
action for BSO and L-PAM,13,19 we determined if enhanced
cytotoxicity from the combination was due to increased apoptosis
by assessing loss of mitochondrial membrane potential.24,41,42 In
all four cell lines tested, we observed a signiﬁcant loss (Po0.05) in
mitochondrial membrane potential because of BSOþ L-PAM
treatment as compared with single agents or controls (Figures
4c and d). For example, in the MM.1S cell line, the percentage of
cells with depolarized mitochondria were 10.9±9.5% in controls,
10.2±8.1% with BSO alone, 45.2±5.3% with L-PAM alone and
63.7±5.7% with BSOþ L-PAM, (Po0.05 for BSOþ L-PAM relative
to single agents and controls).
Figure 3. Anti-myeloma activity of BSO and L-PAM as a single agent and combination in primary MM cells when cultured with MM cytokines at
bone marrow level hypoxia. (a) Dose-response curves of BSO (black circles), L-PAM (white circles) and combination (black triangles). Primary
MM cells were seeded (B10 000), treated with BSO (0–400 mM) for 24 h followed by the treatment with L-PAM (0–50 mM). The cytotoxicity was
determined using DIMSCAN assay at 96 h of incubation with the drugs. Error bars represent s.d. (nX3). (b) List of relevant clinical information
of MM samples. Each sample was collected from different patients. Except for MM-1 all samples were collected from patient who had
significant exposure to chemotherapy. (c) The CIN numbers were calculated as described in Figures 1 and 2.
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BSO increased L-PAM-induced cleavage of caspase-9, caspase-3,
poly ADP ribose polymerase and apoptosis
Mitochondrial membrane depolarization is accompanied by the
discharge of cytochrome-c, formation of apoptosomes and
cleavage of procaspase-9 to caspase-9.41,42 Activation of
caspase-9 initiates the cascade of caspases and cleavage of
critical intracellular proteins.41 In the MM.1S, RPMI-8226 and U266
cell lines, L-PAM±BSO enhanced cleavage of caspase-9, caspase-3
and PARP relative to control and single agents (Figure 5a and
Supplementary Figure 3). We also examined internucleomsomal
DNA fragmentation induced by BSOþ L-PAM using the TUNEL
assay.41,42 Consistent with our data for caspase activation, BSO
signiﬁcantly increased apoptosis induced by L-PAM in all cell lines
tested (Po0.05; Figures 5b and c), although the enhanced
apoptosis in the MM.1S and KMS-12-PE lines was modest in
comparison with the synergistic cytotoxicity (Figure 1) suggesting
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non-apoptotic mechanisms may account for much of the BSO
enhancement in these lines. Apoptosis as a mechanism of
synergistic cytotoxicity was conﬁrmed by demonstrating that
inhibition of caspase cleavage by pan-caspase inhibitor QVD-OPh
signiﬁcantly reversed the cytotoxicity and apoptosis induced by
BSOþ L-PAM (Supplementary Figures 4 and 5).
BSO signiﬁcantly depleted GSH in vitro and in vivo and L-PAM
treatment induced GSH extrusion
BSO signiﬁcantly (Po0.05) depleted GSH in all nine cell lines
(Figure 6a). The mean GSH in controls was 51.4±33.4 ng/mg,
which decreased to 10.4±5.6 ng/mg. In vivo, BSO signiﬁcantly
depleted GSH in xenografted MM cells (control¼ 10.2±1.4 ng/mg
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Figure 5. BSOþ L-PAM treatment induced a significant increase in cleavage of caspase-9, caspase-3, poly ADP ribose polymerase (PARP), and
apoptosis (TUNEL). (a) The MM.1S, RPMI-8226 and U266 cell lines were treated with BSO for 24 h, followed by L-PAM treatment for 24 h. Cells
were lysed, sonicated and centrifuged at 13 000 g for 30min and 50 mg of protein (supernatant) in each sample was resolved by
electrophoresis using 4–12% bis-tris gels, transferred to polyvinylidene difluoride membrane, incubated with antibodies and visualized by
enhanced chemiluminescent substrate. b-Actin served as a loading control. Full-length caspase-9 is 47 kDa protein that is cleaved into 37 and
35 kDa fragment due to L-PAM±BSO treatment. Similarly, caspase-3 (35 kDa) gets cleaved into a small fragment (17/19 kDa), whereas PARP, a
116 kDa protein, forms a large fragment (89 kDa) upon cleavage by caspase-3. (b) MM.1S cells were treated with vehicle, BSO (400 mM), L-PAM
(30mM) and BSOþ L-PAM, collected 48 h after stimulation, fixed, incubated with TdT enzyme and FITC-dUTP for 2 h, counterstained with
propidium iodide and analyzed with flow cytometry as described in Figure 4a. Cells in quadrant-4 (Q4, FITCþ /PI ) were considered to be
apoptotic. (c) BSOþ L-PAM treatment significantly enhanced (Po0.05) percentage of apoptotic cells as compared with single-agent treatment
in MM.1S, KMS-12-PE, OPM-2 and U266 cell lines. Apoptosis data are from flow cytometry analysis as depicted in Figure 5b. The bars represent
mean % apoptosis (± s.d.) and asterisk represents statistical difference in mean (Po0.05).
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Figure 6. Effect of BSO and L-PAM treatment on total GSH (GSHþGSSG). (a) The bars represent the mean GSH (GSHþGSSG) in individual cell
lines±BSO (400 mM) treatment for 24 h. The error bars represent s.d. (b) In a separate experiment, NCI-BNX mice were inoculated with MM.1S
cell line. When progressively growing tumors wereX100mm3, mice were treated with 125mg/kg b.i.d of BSO (total dose 250mg/kg). At 12 h
after the last dose, mice were killed, tumors from controls (n¼ 3) and BSO-treated mice (n¼ 3) were harvested, minced and total GSH was
determined as described in methods. Consistent with the in vitro data, BSO significantly depleted GSH in MM cells in vivo. (c) MM.1S (L-PAM
sensitive, IC90¼ 12.5 mM) and OPM-2 (L-PAM-resistant IC90¼ 52 mM) were treated with L-PAM alone (10mM) or BSOþ L-PAM (400 mMþ10mM) and
total GSH levels were determined using high-performance liquid chromatography (HPLC). The total GSH levels were normalized using total
protein content. Bars represent % of GSH compared with control and error bars represent s.d. (n¼ 3). Asterisk represents statistical difference
in the means (Po0.05). (d) Cells were seeded, treated with BSO for 24 h, NAC (750 or 1000 mM) was added 3 h before the treatment with L-PAM
(0–50 mM) and cells were incubated with drugs for 96 h and the survival fraction was determined using DIMSCAN assay. (e) Cells were seeded,
treated with NAC alone (750 or 1000 mM), or BSOþ L-PAM (400 mMþ10 mM) or NACþ BSOþ L-PAM. The total GSH was determined as described
in Materials and Methods section. Bars represent % GSH compared with control and error bars represent s.d. (n¼ 3) (NS, not significant).
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vs treated 3.3±1.3 ng/mg, Po0.05) (Figure 6b). We also investi-
gated the effect of L-PAM on intracellular GSH in MM.1S (L-PAM-
sensitive, IC90: 12.5 mM) and OPM-2 (L-PAM-resistant, IC90: 52.5 mM)
cell lines. L-PAM treatment signiﬁcantly (Po0.05) depleted GSH in
the MM.1S cell line at 24 and 48 h (Figure 6c). In OPM-2, GSH was
signiﬁcantly depleted at 12 h, recovered by 24 h and maintained at
48 h. However, BSO treatment abolished ability of OPM-2 to
recover GSH that was depleted by L-PAM (Figure 6c).
Treatment with NAC antagonized the synergistic cytotoxicity of
BSOþ L-PAM
To determine if the action of BSO in enhancing L-PAM cytotoxicity
was due to the decreased GSH removing a key intracellular
absorbent of L-PAM, we assessed the cytotoxicity of BSOþ L-PAM
in the presence of the thiol NAC. As shown in Figure 6d,
pretreatment with NAC substantially reversed the cytotoxicity
induced by BSOþ L-PAM in all four cell lines. Highest reversal was
seen in L-PAM-resistant OPM-2 and U266 cell lines. To understand
this observation, we analyzed the GSH levels with NAC±BSOþ
L-PAM treatment. NAC treatment enhanced (Po0.05) the basal
GSH levels byX25%. However, in the presence of BSO, NAC failed
to enhance GSH levels because of the potent inhibition of the
g-GCS by BSO. This observation suggests that protective effect of
NAC is likely to be mediated by GSH-independent mechanisms.43
We also observed that treatment with STS substantially reversed
the effect of BSOþ L-PAM, but for most MM lines non-thiol anti-
oxidants (vitamins C and E) did not alter the cytotoxic synergy of
BSOþ L-PAM (Supplementary Figure 6). These latter data indicate
that the antagonism of BSOþ L-PAM by NAC and STS is not
due to their antioxidant properties or a restoration of GSH, but
likely the thiols (like GSH) bind to and de-toxify L-PAM.
In MM xenografts, BSOþ L-PAM increased apoptosis, induced CRs
and doubled median EFS relative to L-PAM alone
To determine the activity of BSOþ L-PAM in vivo, we established
subcutaneous xenografts in immunocompromised mice from
the MM.1S, OPM-2 and KMS-12-PE cell lines. For all three MM
xenograft models, BSO alone had very low or no activity
(RTV460% and EFS T/Co2) and failed to induce any objective
responses (Figures 7a and b and Table 1). All mice in control and
BSO-treated groups showed PD. In the MM.1S xenograft model,
L-PAM as a single agent was highly active (RTV¼ 11.2% and EFS
T/C¼ 2.5), inducing partial responses in 8/10 and PD in 2/10 mice.
In the OPM-2 xenografts, L-PAM had low activity (RTV¼ 63.9% and
EFS T/C¼ 1.8), with PD observed in 3/5 mice, partial response in
1/5 and CR in 1/5 mice. In the KMS-12-PE xenografts, L-PAM alone
was moderately active (RTV¼ 45.3% and EFS T/C¼ 1.7) and
induced a CR in one mouse (1/6), while the other ﬁve mice had
PD. In contrast to controls and mice treated with single agents,
BSOþ L-PAM had potent activity in all three MM xenograft models
(RTVo45% and EFS T/C42). In MM.1S xenografts, BSOþ L-PAM
induced CRs in all 10 mice and 1 mouse had a maintained
CR (MCR) (CRX100 days). In two of the OPM-2 xenografts, BSOþ
L-PAM reduced tumor volumes of 1330mm3 and 972mm3 to
o50mm3 within 33 and 19 days, respectively, and induced CRs in
7/7 mice, of which 5/7 were MCRs. In KMS-12-PE xenografts, 4/8
mice had CRs, 2/8 had partial responses and 2/8 had PD (Figure 7a
and Table 1). BSOþ L-PAM treated mice lost B23% of initial
body weight but regained weight during the third week
(Supplementary Figure 2).
The median EFS of control groups were 9, 10 and 10 days in
MM.1S, OPM-2 and KMS-12-PE, respectively (Table 1). BSO alone
did not induce any objective responses and the median EFS was
not signiﬁcantly different than controls (MM.1S, OPM-2 and KMS-
12-PE, median EFS¼ 11, 13 and 10 days, respectively). In MM.1S
xenografts, L-PAM alone increased the median EFS by 2.5-fold and
2.0-fold relative to controls and BSO, respectively. In the OPM-2
xenografts, L-PAM alone induced a 1.8-fold increase (18.0 days) in
the median EFS relative to controls (10 days) and 1.3-fold relative
to BSO alone (13 days). In KMS-12-PE, the median EFS after L-PAM
single-agent treatment were increased by 1.7-fold (17.5 days) as
compared with controls (10 days) and BSO (10 days).
In MM.1S xenografts, BSOþ L-PAM treatment increased the
median EFS by 5.8-fold over controls, 4.8-fold compared with BSO
and 2.3-fold relative to L-PAM alone (Po0.001; Figure 7b and
Table 1). For OPM-2 xenografts, BSOþ L-PAM enhanced median-
EFS to 100 days, a 10-fold increase compared with the control
group, 7.6-fold over BSO alone and 5.5-fold compared with L-PAM
alone (Po0.001). In KMS-12-PE xenografts, the median EFS for
BSOþ L-PAM was increased by 4.4-fold over controls and BSO
alone and 2.5-fold compared with L-PAM alone (Po0.001). For all
three xenograft models, log-rank analysis showed that BSOþ
L-PAM treatment signiﬁcantly enhanced (Po0.001) the median
EFS as compared with either single agent or the controls.
Combining survival analysis data from all models demonstrated
that BSOþ L-PAM treatment had a very high activity (RTVo45%
and EFS T/C42), inducing CRs in majority of the mice treated
(21/25), achieving MCRs in 6/25 mice, and doubling the median
EFS relative to L-PAM alone (Po0.001; Figure 7b and Table 1).
We analyzed tumor sections from MM xenografts using TUNEL
immunohistochemistry and found that BSOþ L-PAM treatment
signiﬁcantly enhanced (Po0.05) the fraction of apoptotic nuclei
(82±21.7%) as compared with controls (2.1±2.4%), BSO alone
(3.6±3.5%) and L-PAM alone (13.1±11.1%) (Figures 7c and d).
DISCUSSION
Survival of MM patients has improved signiﬁcantly since the
introduction of proteasome inhibitors and immunomodulatory
drugs.2,44 However, nearly all treated patients either suffer a
relapse or develop refractory disease.1,4–7,44–47 The outcome of
treatment in patients relapsed from bortezomib and thalidomide
or lenalidomide remains poor with a median overall survival of 9
months and EFS of 5 months.7,47 Furthermore, only 44% of
patients achieved a minimal or better response to post-relapse
treatment, while others either have stable disease, progression
or no response.7 Thus, MM remains a largely incurable disease
and therefore there is a need to develop new strategies for
treating MM.4–7
Alkylating agents are common drugs in MM therapy either
as part of induction regimen (cyclophosphamide) or for myeloa-
blative therapy (L-PAM) before SCT.2,33,44 The frequent relapses
with progressive declines in response rates and duration of
response to salvage therapy1,2,5–7,45,46 indicate the development
of drug resistance,1,5,45 suggesting that exploration of novel drug
combinations with ability to overcome resistance to conventional
drugs is one promising approach with the potential to improve
the outcome of existing treatment.8,12,20 Of several known
mechanisms of resistance,8,9,13 increased intracellular GSH has
been shown to be associated with L-PAM resistance in MM,8,10 and
is mainly attributed to upregulation of the g-GCS enzyme.10 BSO is
a potent and speciﬁc inhibitor of g-GCS, originally synthesized by
Grifﬁth et al.,14,15 which has been shown to enhance the anti-
myeloma activity of L-PAM in sensitive (8226/S) and resistant
(8226/LR5) MM cell lines.8 Although this later study demonstrates
chemosensitization to L-PAM by BSO in MM, it was limited to one
cell line from one patient, testing took place in non-physiological
hyperoxic room air conditions,8,26 and BSOþ L-PAM activity
was not assessed in vivo. Furthermore, the dose of BSO used was
B1/5th (100mM) of the clinically achievable levels, as clinical studies
in adults have demonstrated that continuous infusion of BSO
safely achieved B500mM levels when given with L-PAM.12,16,21
Dorr et al.17 demonstrated that pretreatment with BSO enhanced
the activity of L-PAM in a murine plasmacytoma model, but the
activity in human MM xenografts has not been previously explored.
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We have previously demonstrated the ability of BSO to
modulate L-PAM resistance in neuroblastoma cell lines
established at disease progression including those progressing
after myeloablative therapy using L-PAM.20,48 We have shown
that the optimal activity in multidrug-resistant neuroblastoma
cell lines requires use of L-PAM concentrations only achievable
with hematopoietic stem cell support.20 Based on our preclinical
data, a phase I study of dose-escalating L-PAM to myeloablative
levels when given with BSO and supported by autologous stem
cell infusion was recently completed in the NANT consortium
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Figure 7. BSOþ L-PAM treatment induced CRs, and increased the median-EFS relative to L-PAM or BSO alone in MM xenografts. (a) In vivo
activity of L-PAM in combination with BSO against three human MM lines as murine xenografts. NCI BNX mice carrying, MM.1S, OPM-2 and
KMS-12-PE subcutaneous xenografts were treated with BSO (125mg/kg b.i.d for days 1, 2 and 3) and L-PAM (10mg/kg/day for days 2 and 3) as
single agents or in combination. Tumor volumes were measured twice weekly. Individual lines represent tumor volume in a mouse after
initiation of treatment (day 1). Mice were killed when reaching the defined end point (tumor volumeX1500mm3). A CR was defined as tumor
volume p50mm3 and a MCR was defined as a CR that persisted for 100 days. Each group had at least five mice. The study was terminated
after 100 days of initiating treatment and all surviving mice were humanely killed by cervical dislocation. (b) The mouse EFS was calculated as
time from initiating treatment until the end point (tumor volumeX1500mm3 or severe morbidity). The survival distribution for each cohort
was compared using the log-rank test using GraphPad Prism software (La Jolla, CA, USA). BSOþ L-PAM induced44-fold increase (Po0.001) in
median-EFS as compared with controls and42-fold increase (Po0.001) as compared with L-PAM in MM.1S xenograft, in OPM-2, in KMS-12-PE
and for all models combined. (c) Analysis of apoptosis (TUNEL staining) in xenograft MM tumors after BSOþ L-PAM treatment. MM.1S
xenograft mice were treated as described in Materials and Methods section. Tumors were harvested 4–5 days after last treatment, fixed in
formalin, embedded in OCT compound (Tissue Tek, Torrance, CA, USA) and sectioned using a cryostat. The In Situ Cell Death Detection Kit
(Roche Applied Sciences, Indianapolis, IN, USA) was used for TUNEL staining. Images were obtained using a fluorescent microscope (Olympus,
Center Valley, PA, USA; IX71). The images were acquired by Photometric CoolSnap HQ camera (Photometric, Tucson, AZ, USA) using  20
magnification and imported into MetaMorph software (Molecular Device, Sunnyvale, CA, USA). (d) The images were enhanced by digital
thresholding and the percentage of apoptotic cells was calculated as total area occupied by FITC-stained cells/total area occupied by
4,6-diamidino-2-phenylindole-stained cell for the same image. The bars represent the mean % of apoptotic cells±s.d. (n43).
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(www.NANT.org; www.clinicaltrials.gov, NCT00005835) and has
shown that myeloablative L-PAM given with BSO is well tolerated.
As chemotherapy of MM and neuroblastoma both rely heavily on
L-PAM and GSH has been shown to enhance L-PAM resistance in
MM in vitro models,8,10 we determined the potential for BSO to
enhance L-PAM activity in MM.
We demonstrated that BSO synergistically enhanced L-PAM-
induced cytotoxicity for MM in vitro. In the majority of cell lines,
depletion of GSH by 480% was not cytotoxic, whereas three cell
lines were affected by BSO. Our observations are consistent with a
previous clinical study in solid tumors where continuous infusion
of BSO depleted tumor GSH below 10% of pretreatment levels
with minimal systemic toxic effects.16,21 L-PAM as a single agent
was moderately active in ﬁve cell lines and highly active in four
cell lines. BSO potentiated the anti-MM activity of L-PAM, inducing
42 logs of cell kill in MM cell lines with a highly aggressive
phenotype.25,38 As aberrations in the TP53 gene and t(4:14)
translocations are seen in B15% of patients49 and correlated
with short progression-free survival and resistance to alkylating
agents at relapse,50 the ability of BSO to sensitize MM cells
with this phenotype suggests that BSOþ L-PAM may have
clinical activity in the most aggressive forms of MM. Although
BSOþ L-PAM were not as active in the TX-MM-030h cell line
(established at relapse after therapy with myeloablative L-PAM)
as in other cell lines, BSOþ L-PAM had a greater than additive
effect and induced B3 logs of cell kill. Even in the presence of
BMSC and MM cytokines, BSOþ L-PAM induced multi-logs
of synergistic cytotoxicity (CIN o1.0) and apoptosis (Po0.05)
compared with single agents. Similarly, BSO pretreatment
synergistically enhanced (CIN o1.0) L-PAM-induced synergistic
cytotoxicity in primary MM cells explanted from blood and bone
marrows of seven MM patients, six of whom had signiﬁcant
prior exposure to chemotherapy, including myeloablative
therapy and SCT.
The potent anti-myeloma activity of BSOþ L-PAM that we
observed in vitro was also observed in MM xenograft mouse
models. The combination treatment, at a non-myeloablative dose,
that was maximum tolerated by beige-nude-xid mice induced CRs
in 100% of the MM.1S and OPM-2 xenografts, while 25% of mice
achieved a CR in KMS-12-PE xenografts. One of 10 MM.1S mice
and 5/7 OPM-2 mice achieved MCRs. Notably, the combination
was highly active against the OPM-2 xenograft model, which has a
translocation t(4;14).2,50 The doses of BSO (human equivalent dose:
754mg/m2)12 and L-PAM (human equivalent dose: 60mg/m2)33,51
used in our xenograft studies are lower than the clinically
achievable doses in a setting where autologous stem cell support
is used. As we have documented the tolerability of L-PAMþ BSO
when supported by autologous stem cell infusion in heavily
pretreated relapsed and/or refractory neuroblastoma patients
(NANT phase I study, NCT00005835, www.clinicaltrials.gov), using
myeloablative L-PAMþ BSO is clinically feasible. The tolerability of
myeloablative L-PAMþ BSO in our pediatric phase I study taken
together with the preclinical data presented here support the
feasibility of a phase I trial of L-PAMþ BSO in MM.
We showed that BSO alone did not induce apoptosis in MM cell
lines. By contrast, BSO signiﬁcantly enhanced L-PAM-induced
apoptosis and cytotoxicity. The effect of BSO-induced GSH
depletion is likely by thwarting L-PAM detoxiﬁcation and therefore
increasing L-PAM-induced DNA interstrand crosslinks.8–10,13 It is
also possible that GSH depletion affects cellular response
to DNA damage by partially inhibiting DNA repair because of
effects on sulfhydryl-containing repair enzymes and depleting
redox environment necessary for repair machinery.8,52,53 Both
mechanisms of action for BSO could be clinically important
because previous studies have demonstrated that increased DNA
crosslink/monoadducts and slow repair of DNA damage in L-PAM-
treated patients is correlated to longer progression-free survival
and improved outcome of treatment.13,54
Our mechanistic investigations demonstrated that BSOþ
L-PAM induced signiﬁcant increases in mitochondrial depolariza-
tion, cleavage of caspase-3, caspase-9, poly ADP ribose
polymerase and DNA fragmentation. Interestingly, BSO
Table 1. Response induced by BSOþ L-PAM treatment regimen and its effect on mean RTV, T/C %, median EFS and EFS T/C in MM xenograft models
Groups N CR (%) MCR (%) PR (%) PD (%) Mean RTV mm3 T/C (RTV) % Median EFS EFS T/C
MM.1S
Control 5 0 0 0 5 (100) 1368.1 100.00 9 1
BSO 5 0 0 0 5 (100) 1573.2 114.99 11 1.2
L-PAM 10 0 0 8 (80) 2 (20) 153.3 11.20 23 2.5
BSOþ L-PAM 10 10 (100) 1 (10) 0 0 32.3 2.36 53a,b,c 5.8
OPM-2
Control 5 0 0 0 5 (100) 1308.0 100.00 10 1
BSO 5 0 0 0 5 (100) 1367.0 104.51 13 1.3
L-PAM 5 1 (20) 0 1 (20) 3 (60) 835.5 63.88 18 1.8
BSOþ L-PAM 7 7 (100) 5 (71.4) 0 0 412.2 31.51 100a,b,c 10
KMS-12-PE
Control 5 0 0 0 5 (100) 1556.5 100.00 10 1
BSO 5 0 0 0 5 (100) 1557.2 100.04 10 1
L-PAM 6 1 (16.6) 0 0 5 (83.3) 704.8 45.28 17.5 1.7
BSOþ L-PAM 8 4 (50) 0 2 (25) 2 (25) 280.9 18.05 44.5a,b,c 4.4
All models
Control 15 0 0 0 15 (100) 1410.9 100.00 10 1
BSO 15 0 0 0 15 (100) 1499.1 106.26 11 1.1
L-PAM 21 2 (9.5) 0 12 (57) 7 (33) 564.5 40.01 20 2
BSOþ L-PAM 25 21 (84) 6 (24) 2 (8) 2 (8) 241.8 17.14 53a,b,c 5.3
Abbreviations: BSO, buthionine sulfoximine; CR, complete response; EFS, event-free survival; EFS T/C, median EFS of treated group/median EFS of control
group; L-PAM, melphalan; MCR, maintained complete response (4100 days); Mean RTV, mean relative tumor volume on days 8–9; Median EFS, median days
taken to reach end point (tumor volume X1500mm3); MM, multiple myeloma; N, total number of mice in a group; PD, progressive disease; PR, partial
response; T/C (RTV) %, tumor volume of treated group/tumor volume of control on days 8–9. The table indicates best response induced by vehicle, single
agents and combination treatment. aRelative to control Po0.001. bRelative to BSO Po0.001. cRelative to L-PAM Po0.001.
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signiﬁcantly enhanced L-PAM-induced apoptosis in TP53-
mutated MM cell lines, suggesting that BSOþ L-PAM can achieve
p53-independent cell death as described previously.20,55 As p53
abnormalities are associated with poor prognosis in MM,2,49 the
ability of BSOþ L-PAM to induce cell death by circumventing p53
loss-of-function may provide a viable therapeutic option for
patients with del17p13 MM.2,49
L-PAM depleted GSH in the L-PAM-resistant OPM-2 cell line but
GSH rapidly recovered. However, BSO treatment of OPM-2
prevented the GSH recovery after L-PAM treatment. A recent
report showed that basal GSH levels are signiﬁcantly elevated in
MM patients after receiving therapy, which is consistent with our
observation of resistant MM cell lines increasing GSH after L-PAM
treatment.56 Treatment with thiols (NAC and STS) antagonized the
cytotoxic synergy of BSOþ L-PAM, mimicking the effect of GSH as
previously reported.43,57 The effect of NAC is independent of GSH
because in the presence of BSOþ L-PAM, NAC did not increase
GSH levels. Moreover, as non-thiol antioxidants (vitamins C and E)
did not antagonize BSOþ L-PAM cytotoxicity, it is likely that NAC
and STS act to directly replace GSH as an absorbent of the highly
reactive L-PAM.
In conclusion, our study demonstrated that depletion of GSH by
BSO signiﬁcantly enhanced the activity of L-PAM against MM
in vitro and in vivo. A recently completed NANT phase I study
demonstrated that myeloablative BSOþ L-PAM was well tolerated
in neuroblastoma patients. Taken together, these data support the
development of a phase I clinical trial of BSOþmyeloablative
dosing of L-PAM and stem cell support in patients with relapsed
and refractory MM.
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